$6.31
0.539.17%
At close: -
$6.31
0.000.00%
After Hours: Dec 20, 5:25 PM EDT
Comments
Loading...
4D Molecular Therapeutics (NASDAQ:FDMT) Stock, Earnings Estimates, EPS, And Revenue
4D Molecular Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Feb 27
EPS Estimate
$-0.820
Quarterly Revenue Estimate
$2.4M
Annual Revenue
(as of Sep 30)
(as of Sep 30)
$17K
Analyze the earnings history of 4D Molecular Therapeutics using advanced sorting and filters.
Data brought to you by Benzinga APIs
4D Molecular Therapeutics (FDMT) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Sep 2024 | 2024-11-13 | $-0.79 | $-0.70 | -12.9 % |
| Jun 2024 | 2024-08-08 | $-0.63 | $-0.71 | 11.3 % |
| Mar 2024 | 2024-05-09 | $-0.66 | $-0.74 | 10.8 % |
| Dec 2023 | 2024-02-29 | $-0.77 | $-0.74 | -4.05 % |
4D Molecular Therapeutics (FDMT) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Sep 2024 | 2024-11-13 | $3.00K | $560.00K | -99.5 % |
| Mar 2024 | 2024-05-09 | $28.00K | $780.00K | -96.4 % |
| Dec 2023 | 2024-02-29 | $-17.00K | $2.06M | -100.8 % |
| Sep 2023 | 2023-11-09 | $20.20M | $9.87M | 104.7 % |
FAQ
When is 4D Molecular Therapeutics (NASDAQ:FDMT) reporting earnings?
4D Molecular Therapeutics (FDMT) is scheduled to report earnings on February 27, 2025. The last reported earnings were for reported on November 13, 2024 for Q3.
What were the latest earnings per share (EPS) for 4D Molecular Therapeutics (NASDAQ:FDMT)?
The Actual EPS was $-0.79, which missed the estimate of $-0.70.
What were 4D Molecular Therapeutics’s (NASDAQ:FDMT) revenues?
The Actual Revenue was $3K, which missed the estimate of $560K.
Browse earnings estimates, EPS, and revenue on all stocks.